(SY1) Symrise - Ratings and Ratios
Fragrances, Flavorings, Cosmetic Ingredients, Functional Ingredients, Probiotics
SY1 EPS (Earnings per Share)
SY1 Revenue
Description: SY1 Symrise
Symrise AG is a global supplier of fragrances, flavorings, and ingredients for various industries, operating in two main segments: Taste, Nutrition & Health, and Scent & Care. The company provides a range of products, including functional ingredients, savory flavors, and cosmetic ingredients, to manufacturers of food, beverages, perfumes, and personal care products.
From a business perspective, Symrise AG has a diversified revenue stream across different regions, including Europe, North America, and Asia Pacific. The companys Taste, Nutrition & Health segment is likely driven by the demand for natural and sustainable ingredients, while the Scent & Care segment is influenced by the trends in the cosmetics and personal care industry. Key Performance Indicators (KPIs) to watch include revenue growth, segmental margins, and return on invested capital (ROIC).
Analyzing the companys financials, we can observe that Symrise AG has a market capitalization of approximately €12.7 billion, with a price-to-earnings (P/E) ratio of 26.22 and a forward P/E of 22.47. The return on equity (RoE) is 12.35%, indicating a relatively stable profitability. Other relevant KPIs include the debt-to-equity ratio, interest coverage ratio, and operating cash flow margin, which can provide insights into the companys capital structure and cash generation capabilities.
To further evaluate Symrise AGs stock, we can examine its dividend yield, payout ratio, and dividend growth rate, which can indicate the companys commitment to returning value to shareholders. Additionally, analyzing the companys research and development (R&D) expenses as a percentage of revenue can provide insights into its innovation capabilities and potential for future growth.
SY1 Stock Overview
| Market Cap in USD | 13,373m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception |
SY1 Stock Ratings
| Growth Rating | -48.2% |
| Fundamental | 64.2% |
| Dividend Rating | 31.2% |
| Return 12m vs S&P 500 | -39.6% |
| Analyst Rating | - |
SY1 Dividends
| Dividend Yield 12m | 1.32% |
| Yield on Cost 5y | 1.09% |
| Annual Growth 5y | -10.35% |
| Payout Consistency | 96.7% |
| Payout Ratio | 33.1% |
SY1 Growth Ratios
| Growth Correlation 3m | -90.6% |
| Growth Correlation 12m | -77.8% |
| Growth Correlation 5y | -29.5% |
| CAGR 5y | -5.44% |
| CAGR/Max DD 5y | -0.14 |
| Sharpe Ratio 12m | -1.08 |
| Alpha | -35.03 |
| Beta | 0.110 |
| Volatility | 29.62% |
| Current Volume | 370k |
| Average Volume 20d | 335.8k |
| Stop Loss | 80.2 (-3.1%) |
| Signal | 0.06 |
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (626.6m TTM) > 0 and > 6% of Revenue (6% = 376.2m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -4.83pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 14.74% (prev 37.92%; Δ -23.18pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 1.02b > Net Income 626.6m (YES >=105%, WARN >=100%) |
| Net Debt (1.84b) to EBITDA (756.4m) ratio: 2.43 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.49 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (139.8m) change vs 12m ago -0.19% (target <= -2.0% for YES) |
| Gross Margin 40.08% (prev 36.64%; Δ 3.44pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 80.17% (prev 60.75%; Δ 19.42pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 9.50 (EBITDA TTM 756.4m / Interest Expense TTM 55.6m) >= 6 (WARN >= 3) |
Altman Z'' 2.60
| (A) 0.12 = (Total Current Assets 2.80b - Total Current Liabilities 1.88b) / Total Assets 7.73b |
| (B) 0.25 = Retained Earnings (Balance) 1.94b / Total Assets 7.73b |
| (C) 0.07 = EBIT TTM 527.9m / Avg Total Assets 7.82b |
| (D) 0.52 = Book Value of Equity 2.08b / Total Liabilities 4.02b |
| Total Rating: 2.60 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 64.16
| 1. Piotroski 8.0pt = 3.0 |
| 2. FCF Yield 1.23% = 0.61 |
| 3. FCF Margin 2.43% = 0.61 |
| 4. Debt/Equity 0.34 = 2.44 |
| 5. Debt/Ebitda 1.68 = 0.63 |
| 6. ROIC - WACC 0.52% = 0.65 |
| 7. RoE 16.24% = 1.35 |
| 8. Rev. Trend 10.85% = 0.54 |
| 9. Rev. CAGR 4.54% = 0.57 |
| 10. EPS Trend 49.92% = 1.25 |
| 11. EPS CAGR 135.1% = 2.50 |
What is the price of SY1 shares?
Over the past week, the price has changed by -1.69%, over one month by -3.74%, over three months by -20.40% and over the past year by -29.37%.
Is Symrise a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SY1 is around 72.52 EUR . This means that SY1 is currently overvalued and has a potential downside of -12.39%.
Is SY1 a buy, sell or hold?
What are the forecasts/targets for the SY1 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 109.8 | 32.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 78.9 | -4.7% |
SY1 Fundamental Data Overview
Market Cap EUR = 11.48b (11.48b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 369.7m EUR (last quarter)
P/E Trailing = 22.6281
P/E Forward = 21.1416
P/S = 2.3022
P/B = 3.1438
P/EG = 2.4307
Beta = 0.51
Revenue TTM = 6.27b EUR
EBIT TTM = 527.9m EUR
EBITDA TTM = 756.4m EUR
Long Term Debt = 1.27b EUR (from longTermDebt, last quarter)
Short Term Debt = unknown (0.0)
Debt = 1.27b EUR (Calculated: Short Term 0.0 + Long Term 1.27b)
Net Debt = 1.84b EUR (from netDebt column, last fiscal year)
Enterprise Value = 12.38b EUR (11.48b + Debt 1.27b - CCE 369.7m)
Interest Coverage Ratio = 9.50 (Ebit TTM 527.9m / Interest Expense TTM 55.6m)
FCF Yield = 1.23% (FCF TTM 152.1m / Enterprise Value 12.38b)
FCF Margin = 2.43% (FCF TTM 152.1m / Revenue TTM 6.27b)
Net Margin = 9.99% (Net Income TTM 626.6m / Revenue TTM 6.27b)
Gross Margin = 40.08% ((Revenue TTM 6.27b - Cost of Revenue TTM 3.76b) / Revenue TTM)
Tobins Q-Ratio = 5.95 (Enterprise Value 12.38b / Book Value Of Equity 2.08b)
Interest Expense / Debt = 0.30% (Interest Expense 3.78m / Debt 1.27b)
Taxrate = 25.37% (from yearly Income Tax Expense: 163.8m / 645.8m)
NOPAT = 394.0m (EBIT 527.9m * (1 - 25.37%))
Current Ratio = 1.49 (Total Current Assets 2.80b / Total Current Liabilities 1.88b)
Debt / Equity = 0.34 (Debt 1.27b / last Quarter total Stockholder Equity 3.71b)
Debt / EBITDA = 1.68 (Net Debt 1.84b / EBITDA 756.4m)
Debt / FCF = 8.34 (Debt 1.27b / FCF TTM 152.1m)
Total Stockholder Equity = 3.86b (last 4 quarters mean)
RoA = 8.11% (Net Income 626.6m, Total Assets 7.73b )
RoE = 16.24% (Net Income TTM 626.6m / Total Stockholder Equity 3.86b)
RoCE = 10.30% (Ebit 527.9m / (Equity 3.86b + L.T.Debt 1.27b))
RoIC = 6.33% (NOPAT 394.0m / Invested Capital 6.23b)
WACC = 5.80% (E(11.48b)/V(12.75b) * Re(6.42%)) + (D(1.27b)/V(12.75b) * Rd(0.30%) * (1-Tc(0.25)))
Shares Correlation 5-Years: 35.90 | Cagr: 0.04%
Discount Rate = 6.42% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 73.52% ; FCFE base≈306.5m ; Y1≈232.2m ; Y5≈141.4m
Fair Price DCF = 19.06 (DCF Value 2.66b / Shares Outstanding 139.8m; 5y FCF grow -28.75% → 3.0% )
Revenue Correlation: 10.85 | Revenue CAGR: 4.54%
Rev Growth-of-Growth: 44.90
EPS Correlation: 49.92 | EPS CAGR: 135.1%
EPS Growth-of-Growth: -75.44